Academic Credentials
  • M.S., Environmental Health Sciences, University of California, Berkeley, 2020
  • B.A., Chemistry, Pepperdine University, 2018
  • B.S., Biology, Pepperdine University, 2018
Licenses & Certifications
  • RAC-Drugs Certified Professional
Additional Education & Training
  • Managing the COVID-19 Pandemic, UC Berkeley, 2020
  • Contact Tracing for COVID-19, Johns Hopkins University, 2020
Professional Affiliations
  • Society of Toxicology (Associate Member), 2021-present
  • International Society of Pharmacoepidemiology, 2025-Present
  • International Society of Pharmacovigilance, 2024-Present
  • • Women’s Medicines Special Interest Group
  • • Real-World Evidence and Big Data Special Interest Group
  • • PV in the Community Special Interest Group
Languages
  • Mandarin Chinese

Ms. Dahlberg is an interdisciplinary health scientist specializing in the integration of epidemiologic, clinical, toxicologic, and mechanistic evidence to conduct weight-of-evidence assessments, evaluate causation, and characterize human health risks, in support of litigation support for legal counsel and scientific and regulatory challenges faced by life science clients.

Ms. Dahlberg has extensive experience leading and conducting systematic literature reviews and meta-analyses under multiple scientific and regulatory frameworks including PRISMA, NTP OHAT, and EPA epidemiology evaluation guidance for evidence integration. Her work has been utilized to support regulatory submissions to the FDA, formed the scientific basis for expert reports in pharmacoepidemiology litigation matters, and has been published in the peer-reviewed literature. She routinely conducts critical appraisals of epidemiologic study design and data quality, including study quality and risk-of-bias evaluations consistent with U.S. EPA guidance, and applies quantitative and qualitative methods to synthesize complex scientific evidence. She is experienced in applying Bradford Hill criteria and conducting general and specific causation analyses consistent with regulatory and legal evidentiary standards.

Ms. Dahlberg's human health risk assessment experience includes evaluating hazards and exposures to a variety of chemical agents, such as volatile and semi-volatile organic compounds (e.g., benzene, methacrylates, toluene), metals / metalloids (e.g., lead, arsenic, cadmium, nickel), perflourinated compounds (e.g., perfluorooctanoic acid or PFOS), silicates (e.g., asbestos, crystalline silica), BPA, and pesticides (e.g., atrazine), across occupational, environmental, and consumer product exposure scenarios. She is well-versed at applying the "Key Characteristics" framework adopted by the International Agency for Research on Cancer (IARC) for hazard assessment of chemicals.

She has also evaluated US FDA and EU EMA regulatory requirements for drug product lifecycles and has provided consulting services to life science clients on clinical development strategy, regulatory submissions, and post-market surveillance, including adverse drug event assessment using pharmacovigilance databases (e.g. FAERS).

Prior to joining Exponent, Ms. Dahlberg received her M.S. in environmental health sciences with a concentration in toxicology from UC Berkeley School of Public Health, and B.S./B.A. degrees in biology and chemistry, respectively from Pepperdine University.